Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA? (lenvatinib) Plus KEYTRUDA? (pembrolizumab) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials